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Hepatitis C virus (HCV) is a major health problem. However, the mechanism of hepatocyte infection is
largely unknown. We demonstrate that the dendritic cell (DC)-specific C-type lectin DC-SIGN and its liver-
expressed homologue L-SIGN/DC-SIGNR are important receptors for HCV envelope glycoproteins E1 and E2.
Mutagenesis analyses demonstrated that both HCV E1 and E2 bind the same binding site on DC-SIGN as the
pathogens human immunodeficiency virus type 1 (HIV-1) and mycobacteria, which is distinct from the cellular
ligand ICAM-3. HCV virus-like particles are efficiently captured and internalized by DCs through binding of
DC-SIGN. Antibodies against DC-SIGN specifically block HCV capture by both immature and mature DCs,
demonstrating that DC-SIGN is the major receptor on DCs. Interestingly, internalized HCV virus-like parti-
cles were targeted to nonlysosomal compartments within immature DCs, where they are protected from
lysosomal degradation in a manner similar to that demonstrated for HIV-1. Lewis X antigen, another ligand
of DC-SIGN, was internalized to lysosomes, demonstrating that the internalization pathway of DC-SIGN-
captured ligands may depend on the structure of the ligand. Our results suggest that HCV may target
DC-SIGN to “hide” within DCs and facilitate viral dissemination. L-SIGN, expressed by THP-1 cells, inter-
nalized HCV particles into similar nonlysosomal compartments, suggesting that L-SIGN on liver sinusoidal
endothelial cells may capture HCV from blood and transmit it to hepatocytes, the primary target for HCV. We
therefore conclude that both DCs and liver sinusoidal endothelial cells may act as reservoirs for HCV and that
the C-type lectins DC-SIGN and L-SIGN, as important HCV receptors, may represent a molecular target for
clinical intervention in HCV infection.
Hepatitis C virus (HCV) is the causal agent of hepatitis C,
which is a major health problem affecting 170 million people
worldwide (1). Approximately 90% of patients develop chronic
hepatitis (11), of which 20 to 30% progress to liver cirrhosis
and end-stage liver disease (20, 43). HCV is an enveloped
positive-stranded RNA virus (8) that belongs to the Flaviviri-
dae family. The genome encodes a single polyprotein (24, 44),
and a combination of host and viral peptidases process the
polyprotein into at least nine different structural and nonstruc-
tural proteins (21, 23, 29). The HCV envelope is formed by two
heavily N-glycosylated type I transmembrane envelope glyco-
proteins E1 (31 kDa) and E2 (70 kDa) (28, 33, 34), which are
expressed as heterodimers on the virus membrane (34).
A characteristic feature of HCV is the high incidence of
persistent infection and chronic hepatitis with a strong risk for
the development of hepatocellular carcinoma, although some
patients exhibit acute self-limited infection (10). This high in-
cidence of chronicity suggests that the virus has developed
efficient mechanisms to escape host immune responses. In-
deed, cellular immune responses are weak in chronically in-
fected patients (7, 32, 39), although the reason for this poor
reaction remains unclear.
HCV infects mainly hepatocytes but also peripheral blood
mononuclear cells. However, the precise mechanisms of early
HCV infection are largely unknown, especially how HCV in-
fects hepatocytes in the liver. Attempts to elucidate these early
events have been hampered by the difficulty in obtaining suf-
ficient amounts of free virions from either the plasma of in-
fected individuals or in vitro systems for virus propagation.
Nevertheless, it is generally accepted that HCV envelope gly-
coproteins E1 and E2, as in other enveloped viruses, may play
a major role in virus binding and entry into target cells. Indeed,
several putative HCV receptors that interact with the HCV
envelope glycoproteins, such as CD81 (36), the scavenger re-
ceptor class B type I (42), and the asialoglycoprotein receptor
(41), have been identified. Recently, it was demonstrated that
the C-type lectins DC-SIGN and L-SIGN/DC-SIGNR may be
involved in HCV binding through their interaction with HCV
envelope glycoprotein E2 (14, 31, 38).
DC-SIGN is specifically expressed on dendritic cells (DCs)
(16, 25), and plays a key role in the dissemination of human
immunodeficiency virus type 1 (HIV-1) by DCs through HIV-1
gp120 binding (15). Recent studies have demonstrated that
DC-SIGN also functions as a receptor for other pathogens,
including cytomegalovirus (22), Ebola virus (2), and Mycobac-
terium tuberculosis (19). It is becoming clear that other patho-
gens besides HIV-1 target DC-SIGN to promote their survival,
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and similarly, HCV binding to DC-SIGN may not only pro-
mote HCV dissemination but also modulate DC function nec-
essary for establishing chronic infections. Indeed, it has been
shown that chronic HCV infection impairs DC maturation as
well as their immune stimulatory function (3, 4). Thus, DCs
may be a target for HCV to escape immune surveillance, and
knowledge about the interaction of DCs with HCV is essential
to fully understand and combat HCV infections.
L-SIGN, the liver homologue of DC-SIGN, is specifically
expressed by liver sinusoidal endothelial cells (LSECs) (5, 37),
a specialized endothelial cell type with antigen-presenting cell
function (26). L-SIGN, like DC-SIGN, binds HIV-1 gp120 and
may be involved in HIV-1 transmission to T cells (5). Similarly,
L-SIGN expressed by LSECs may capture HCV from blood
and mediate infection of adjacent hepatocytes, the main target
cells for HCV.
In order to unravel the interaction of HCV with both C-type
lectins DC-SIGN and L-SIGN and their roles in virus dissem-
ination, we investigated the interaction of both C-type lectins
with virus-like particles (VLPs) consisting of either HCV gly-
coprotein E1 or E2 alone or an E1/E2 heterocomplex as a
suitable surrogate for native HCV particles. We demonstrate
that the C-type lectins DC-SIGN and L-SIGN interact simi-
larly with both glycoproteins E1 and E2 and that the HCV
glycoproteins occupy the same binding pocket in DC-SIGN as
HIV-1 gp120 and mycobacterial mannosylated lipoarabino-
mannan (ManLAM). Both immature and mature DCs strongly
bind the VLPs of E1 and E2, and this interaction is primarily
mediated by DC-SIGN. Moreover, VLPs are rapidly internal-
ized by DC-SIGN on immature DCs and targeted to EEA-1-
positive early endosomes, where the VLPs are protected from
degradation. In contrast, Lewis X (Lex) antigens are internal-
ized by DC-SIGN and targeted to lysosomes for destruction.
Furthermore, we demonstrate that LSECs efficiently capture
HCV particles in situ through L-SIGN. L-SIGN rapidly inter-
nalizes HCV into early endosomes. Our data suggest that HCV
may target DC-SIGN and L-SIGN to hide within DCs and
LSECs, respectively.
MATERIALS AND METHODS
Antibodies and proteins. The following antibodies were used: mouse anti-MR
(clone 19; BD Pharmingen, San Diego, Calif.), DC-SIGN-specific mouse anti-
body AZN-D1 (16), DC-SIGN- and L-SIGN-specific antibody AZN-D2 (22),
mouse anti-L-SIGN (R&D Systems, Minneapolis, Minn.), mouse anti-LAMP-1
(H4A3; BD Pharmingen, San Diego, Calif.), mouse anti-EEA-1 (BD Pharmin-
gen), human and mouse anti-HCV E1 (1C4 and 23C12, respectively; Innogenet-
ics, Ghent, Belgium) and mouse anti-E2 antibody (4H6B2; Innogenetics), goat
anti-human immunoglobulin G1 conjugated with fluorescein isothiocyanate
(FITC) and peroxidase (Jackson Immunoresearch, West Grove, Pa.), goat anti-
mouse conjugated with FITC (Zymed Laboratories Inc., South San Fransisco,
Calif.) goat anti-mouse conjugated with Alexa fLuor 488 and 594 and streptavi-
din Alexa Fluor 488 (Molecular Probes, Eugene, Oreg.).
HIV-1 gp120 was obtained through the AIDS Research and Reference Re-
agent Program, Division of AIDS (National Institutes of Health; HIV-1 IIIB
gp120).
HCV envelope glycoproteins. HCV envelope glycoproteins E1 and E2 were
expressed separately either in Vero cells by infection with recombinant vaccinia
virus or in the yeast Hansenula polymorpha. Both glycoproteins were derived
from the structural region of a genotype 1b isolate and lacked the C-terminal
membrane anchor (E1, amino acids 192 to 326; and E2, amino acids 384 to 673).
A C-terminal His tag was added for purification purposes except for the E1
protein produced in Vero cells.
Despite the truncation of the membrane anchor, all proteins were retained
intracellularly and were thus purified from cell lysates. In brief, the envelope
proteins as expressed in Vero cells were extracted by means of Triton X-100 and
purified by lentil affinity chromatography, resulting in an E1- or E2-enriched
protein fraction consisting mainly of aggregated material. These aggregates were
reduced to monomeric proteins by incubation with dithiothreitol and Empigen
BB. After blocking of the free cysteines with iodoacetamide, the monomeric E1
protein was recovered by size exclusion chromatography in the presence of
Empigen BB. For the E2 protein, both size exclusion chromatography and nickel
metal affinity chromatography were required to obtain pure E2 monomers. In
case of expression in yeast cells, the cells were lysed by means of guanidinium
HCl and sulfonation. The recovered proteins were purified by nickel metal
affinity chromatography in the presence of Empigen BB. Finally, the proteins
were reduced by incubation with dithiothreitol and free cysteines were blocked
with iodoacetamide.
Vero cell- and yeast cell-derived monomeric E1, E2, and equimolar mixtures
of E1 and E2 were subjected to an additional size exclusion chromatography in
the presence of betaine. This step allowed exchange of the detergent Empigen,
resulting in the formation of particles ranging in size from 10 to 100 nm.
Cells. Immature DCs were cultured as described before (40). In short, human
blood monocytes were isolated from buffy coats by a Ficoll and a 52% Percoll
gradient and subsequently an adherence step. Adherent monocytes were differ-
entiated into immature DCs in the presence of interleukin-4 and granulocyte-
macrophage colony-stimulating factor (500 and 800 U/ml, respectively; Schering-
Plough, Brussels, Belgium). At day 6, the phenotype of the cultured DCs was
confirmed by flow cytometric analysis. The DCs expressed high levels of major
histocompatibility complex class I and II, CD11b, CD11c, and ICAM-1 and low
levels of CD80 and CD86. DCs were matured by adding lipopolysaccharide
(LPS, 2 g/ml, Salmonella typhosa; Sigma Aldrich, St. Louis, Mo.) for 2 days.
Maturation was verified by analysis of the expression of CD80, CD83, and CD86.
Stable THP-1 and K562 transfectants expressing wild-type L-SIGN, DC-
SIGN, or DC-SIGN mutants (17) were generated as previously described (15).
Soluble DC-SIGN-Fc binding ELISA. The DC-SIGN-Fc chimera (17) con-
tained the extracellular portion of DC-SIGN (amino acid residues 64 to 404)
fused at the C terminus to a human immunoglobulin G1-Fc fragment. The
soluble DC-SIGN-Fc binding assay was performed as previously described (17).
Soluble ligands were coated on enzyme-linked immunosorbent assay (ELISA)
plates (Maxisorb plate; Nunc; 0.25 g/well unless indicated) overnight at 4°C,
followed by blocking with 1% bovine serum albumin for 30 min at 37°C. Soluble
DC-SIGN-Fc (5 g/ml) was added for 2 h at 37°C, and binding was determined
by an anti-immunoglobulin G1 ELISA. Specificity was determined (unless indi-
cated) in the presence of 50 g of blocking antibodies or 100 g of mannan per
ml or 10 mM EGTA.
Fluorescent bead adhesion assay. Binding of ligand-coated beads to cells was
done as described by Geijtenbeek et al. (16). In short, streptavidin was covalently
coupled to carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 m; Mo-
lecular Probes). The streptavidin-coated beads were incubated with biotinylated
F(ab)2 fragment goat anti-mouse immunoglobulin G (6 g/ml; Jackson Immu-
noresearch), followed by overnight incubation with mouse anti-HCV E1 or E2
antibody (23C12 or 4H6B2) at 4°C. The beads were washed and incubated with
250 ng of purified HCV envelope glycoprotein E1 or E2 per ml overnight at 4°C.
The fluorescent bead adhesion assay was performed as described before (18). In
short, 50,000 cells were incubated with beads for 45 min at 37°C. Mannan,
EGTA, and blocking antibodies against DC-SIGN and L-SIGN were used to
determine the specificity of adhesion. Binding was measured by fluorescence-
activated cell sorting analysis.
DC activation. Immature DCs (0.12  106 cells/ml) were cultured in the
presence of interleukin-4 (500 U/ml; Schering-Plough) and granulocyte-mac-
rophage colony-stimulating factor (800 U/ml; Schering-Plough). The effect of
HCV on activation was determined by incubating immature DCs (day 6) with
HCV VLPs (12.5 g/ml) in the absence or presence of LPS (10 ng/ml) for 48 h
at 37°C. Activation was determined by cell surface expression of the costimula-
tory molecules CD83 and CD86 with phycoerythrin-conjugated antibodies.
Immunofluorescence microscopy. Cells were incubated for 4 h or overnight at
37°C with HCV E1/E2 (30 g/ml) or biotinylated Lex antigen (10 g/ml). The
transferrin receptor was detected by incubating the cells with Alexa Fluor 594-
conjugated transferrin (10 g/ml; Molecular Probes) for 15 min at 37°C prior to
fixation. Labeled cells were fixed in 3% paraformaldehyde in phosphate-buffered
saline for 15 min and permeabilized in phosphate-buffered saline–0.1% saponin
prior to staining. Cells were stained in phosphate-buffered saline–0.5% bovine
serum albumin with antibodies against HCV envelope glycoprotein E1 or E2 and
against LAMP-1, EEA-1, or DC-SIGN and subsequently with FITC- or Alexa
Fluor 488/594-conjugated secondary antibodies or with streptavidin-Alexa Fluor
488. Next, cells were allowed to adhere to poly-L-lysine-coated glass slides and
mounted in antibleach reagent. Fixed slides were either imaged with a Zeiss
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Axiovert 200 Marianas inverted microscope (Intelligent Imaging Innovations,
Denver, Colo.) equipped with a motorized stage (stepper-motor z axis incre-
ments, 0.1 m), multiple fluorescence as well as bright-field channels, and a
Cooke Sensicam cooled charge-coupled device camera (Cooke, Tonawanda,
N.Y.; 1,280 by 1,024 pixels) with true 16-bit capability at 40 objective or
examined with a Nikon Eclipse E800 fluorescence microscope, and pictures were
captured with a digital Nikon DXM1200 camera at 40 objective. In both cases
images were acquired in three independent series or sessions. Pictures were
analyzed with SlideBook 4 digital microscopy software (Intelligent Imaging In-
novations) or Jasc Paint Shop Pro software.
Liver section staining. Human liver tissue was obtained from biopsies of
therapeutic surgeon and cryofrozen; 8-m sections were placed on gelatin-
coated slides and stored at 80°C. The sections were incubated with HCV VLPs
(10 g/ml) for 2 h and stained with the mouse anti-HCV antibody 23C12 and an
Alexa Fluor 594-conjugated secondary antibody or with the human anti-HCV
antibody 1C4 and a FITC-conjugated secondary antibody. Binding of HCV
envelope glycoprotein was blocked by incubation in the presence of 50 g of
antibody AZN-D2 per ml. L-SIGN was detected by staining the liver sections
with an anti-L-SIGN antibody and Alexa Fluor 594-conjugated secondary anti-
body.
Sections were analyzed with a Nikon Eclipse E800 fluorescence microscope,
and pictures were captured with a digital Nikon DXM1200 camera at 20
objective.
RESULTS
DC-SIGN interacts with HCV envelope glycoproteins E1
and E2. The interaction of DC-SIGN with HCV envelope
glycoproteins was investigated with the DC-SIGN-Fc binding
assay (17). Purified HCV envelope glycoproteins E1 and E2
produced in either mammalian cells or the yeast H. polymorpha
are reconstituted into VLPs. Recombinant DC-SIGN-Fc spe-
cifically interacted with both mammalian and yeast HCV en-
velope glycoproteins E1, E2, and mixed E1/E2 VLPs. This
interaction could be blocked by the DC-SIGN-specific anti-
body AZN-D1, the calcium chelator EGTA, and the polycar-
bohydrate mannan (Fig. 1A). No difference in binding was
observed between yeast and mammalian envelope glycopro-
teins (Fig. 1A).
Further experiments were performed with HCV envelope
glycoproteins produced in mammalian cells. DC-SIGN bound
more strongly to glycoprotein E2 than to E1 (Fig. 1B), and the
binding could be specifically blocked by anti-DC-SIGN anti-
bodies (Fig. 1B). The interaction of DC-SIGN with HCV en-
velope glycoproteins E1 and E2 was further investigated by
titration of mannan to block the interaction. Mannan could
completely block the interaction of DC-SIGN with both E1
and E2 (Fig. 1C), although higher concentrations of mannan
were necessary to block HCV E2 binding than to block HCV
E1 and HIV-1 gp120 binding to DC-SIGN (Fig. 1C). This
indicates that DC-SIGN has the same affinity for HCV glyco-
protein E1 and HIV-1 gp120 and a higher affinity for HCV
glycoprotein E2.
The calcium dependency of the DC-SIGN interaction with
the HCV envelope glycoproteins was investigated. The inter-
action of DC-SIGN with HCV envelope glycoproteins E1 and
E2 and HIV-1 gp120 was equally dependent on calcium (Fig.
1D) with the calcium concentration at which binding is half of
the maximum binding (Ki50) between 0.15 and 0.25 mM. At
calcium concentrations lower than 0.1 mM, the binding of
these three ligands was almost completely abolished. These
data demonstrate that DC-SIGN binds both HCV glycoprotein
E1 and E2 as well as HIV-1 gp120.
Cellular DC-SIGN and L-SIGN bind to HCV envelope gly-
coproteins. K562 cells stably expressing DC-SIGN and
L-SIGN were used to investigate the binding of cellular DC-
SIGN and L-SIGN to HCV envelope glycoproteins. The trans-
fectants expressed similar high levels of DC-SIGN and L-SIGN
(Fig. 2A), as shown with the DC-SIGN- and L-SIGN-specific
antibody AZN-D2. K562 transfectants expressing either DC-
SIGN or L-SIGN strongly bound to both HCV envelope gly-
coproteins E1 and E2 (Fig. 2B), whereas mock-transfected
K562 cells did not bind the HCV glycoproteins (data not
shown). The observed binding of both DC-SIGN and L-SIGN
to the HCV glycoproteins was comparable and could be com-
pletely blocked by antibodies against DC-SIGN and L-SIGN
(Fig. 2B).
We used DC-SIGN mutants containing specific mutations in
their ligand-binding site in order to investigate the binding site
of DC-SIGN for HCV envelope glycoprotein E1 and E2 in
more detail. The C-type lectin domain of DC-SIGN contains
two calcium binding sites (16): site 1, positioned at the auxiliary
site of DC-SIGN, and site 2, located near the primary ligand
binding site. The Ca2 ion at site 1 coordinates the correct
positioning of the loops forming the primary binding site (13,
17). To investigate the role of this calcium ion, four mutations
were generated. Mutating Asp320 (D320A), Glu324 (E324A),
Asn350 (N350A), or Asp355 (D355A) to alanine resulted in the
loss of calcium binding at site 1 and subsequent loss of binding
to HCV envelope glycoproteins (Table 1), as was also previ-
ously shown for both ICAM-3 and HIV-1 gp120 (17). Chang-
ing Asp366, which coordinates calcium binding at site 2, to an
alanine residue (D366A) resulted in complete loss of binding
to both HCV and HIV-1 glycoproteins (Table 1). The amino
acid residues that are in close contact with the Ca2 at site 2
(Glu347, Asn349, Glu354, and Asn365) form the core of the
ligand-binding site (17). Changing Glu347 (E347Q) to Gln or
Asn349 (N349D) and Asn365 (N365D) to Asp also resulted in
complete loss of binding to HCV envelope glycoproteins E1
and E2 and HIV-1 gp120 (Table 1).
Recently, we demonstrated that the binding site of DC-
SIGN for its cellular ligand ICAM-3 is distinct from that of its
pathogen ligands HIV-1 gp120 (17) and mycobacterial
ManLAM (19), since a specific mutation in DC-SIGN
(V351G) abolished ICAM-3 but not HIV-1 gp120 and Man-
LAM binding. Interestingly, the DC-SIGN V351G mutant also
interacted with HCV E1 as well as E2 (Fig. 2C), demonstrating
that both HIV-1 and HCV bind similarly to DC-SIGN at a site
distinct from that of the cellular ligand ICAM-3.
HCV VLPs are internalized by DC-SIGN and L-SIGN trans-
fectants. DC-SIGN can function as an antigen receptor, inter-
nalizing antigens (12). With a DC-SIGN-specific antibody as
an antigen, it was shown that DC-SIGN rapidly targets the
antigen to lysosomal compartments for degradation and sub-
sequent presentation on major histocompatibility complex
class II (12). In order to investigate the internalization and
intracellular targeting of HCV VLPs after capture by both
DC-SIGN and L-SIGN, we used stable transfectants of the
erythroleukemic cell line K562 and the monocytic cell line
THP-1. Both DC-SIGN- and L-SIGN-transfected K562 and
THP-1 cells efficiently bound HCV E1/E2 VLPs (Fig. 3A).
Transfectants were incubated overnight with E1 AND E2
VLPs. Intracellular compartments were subsequently stained
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interaction. (C) DC-SIGN has a higher affinity for envelope glycopro-
tein E2 than for envelope glycoproteins E1 and gp120. Mammalian
cell-produced glycoproteins E1 and E2 (10 nM) and gp120 (2 nM)
were coated, and DC-SIGN-Fc binding was determined as described
above. Mannan was titrated (0 to 1,000 g/ml) to block the interaction.
Binding is represented as a percentage of maximal binding. (D) DC-
SIGN binding to HCV envelope glycoproteins E1 and E2 and HIV-1
envelope gp120 is equally dependent on calcium. Viral envelope gly-
coproteins E1 and E2 (10 nM) and gp120 (2 nM) were coated, and
DC-SIGN-Fc binding was measured as described above in the pres-
ence of calcium (0 to 5 mM). Binding is represented as a percentage of
maximal binding at 5 mM calcium. Standard deviations were 2%.
FIG. 1. DC-SIGN specifically binds HCV envelope glycoproteins
E1 and E2. (A) DC-SIGN binds both H. polymorpha and mammalian
cell-produced HCV envelope glycoproteins. DC-SIGN interaction
with HCV envelope glycoproteins E1 and E2 (0.25 g/well) produced
by either the yeast H. polymorpha or mammalian cells with a recom-
binant vaccinia virus, was determined in an Fc-based ELISA. The
specificity of the binding was confirmed with the DC-SIGN-specific
blocking antibody AZN-D1 (50 g/ml), mannan (100 g/ml), and the
calcium chelator EGTA (5 mM). (B) DC-SIGN binds more strongly to
HCV envelope glycoprotein E2 than to E1. HCV glycoproteins E1 and
E2 were titrated (0 to 16 and 0 to 14 M, respectively), and DC-
SIGN-Fc binding was determined as described above. DC-SIGN-spe-
cific antibody AZN-D1 (50 g/ml) was used to specifically block the
FIG. 2. HCV envelope glycoproteins are bound by cellular DC-
SIGN and L-SIGN. (A) K562 transfectants express similar levels of
DC-SIGN and L-SIGN. K562 cells were transfected with DC-SIGN or
L-SIGN as described in Materials and Methods. Expression was mea-
sured by fluorescence-activated cell sorting staining with the DC-
SIGN- and L-SIGN-specific antibody AZN-D2. Dotted lines represent
the isotype control, and black lines represent AZN-D2 staining. Mean
fluorescence indices were 700. (B) Cellular DC-SIGN and L-SIGN
bind to both envelope glycoproteins E1 and E2. HCV envelope glyco-
protein binding by K562 cells expressing DC-SIGN or L-SIGN was
measured with a fluorescently coated bead adhesion assay. The L-
SIGN- and DC-SIGN-specific blocking antibody AZN-D2 (50 g/ml)
was used to determine the specificity of the interaction. (C) The DC-
SIGN Val351 mutant binds both HCV envelope glycoproteins E1 and
E2. Binding of K562 cells transfected with DC-SIGN V351G to gly-
coprotein E1- and E2-coated beads was investigated in the presence
and absence of the DC-SIGN-specific antibody AZN-D2 (50 g/ml)
and EGTA (10 M). Standard deviations were 5%.
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with an antibody against LAMP-1, a marker for lysosomal and
late endosomal vesicles, and with transferrin, which accumu-
lates in early endosomes through transferrin receptor uptake
(9). Cells were analyzed by immunofluorescence microscopy.
In all transfectants, HCV VLPs were rapidly internalized by
DC-SIGN and L-SIGN and targeted to the endosomal path-
way (Fig. 3B). Remarkably, our results demonstrate that the
internalization pathway of both DC-SIGN and L-SIGN is de-
pendent on the cell type. Both DC-SIGN and L-SIGN ex-
pressed by K562 cells targeted HCV E1/E2 VLPs to the
LAMP-1-positive compartments (Fig. 3B), not to the trans-
ferrin-positive early endosomes (Fig. 3C). In contrast, HCV
VLPs internalized by DC-SIGN and L-SIGN expressed by
THP-1 cells were not targeted to the lysosomes. In these cells,
HCV VLPs resided not within LAMP-1-positive compart-
ments (Fig. 3D) but in transferrin-positive vesicles (Fig. 3E).
The internalization was specific for both DC-SIGN and L-
SIGN, since both mock-transfected K562 and THP-1 cells did
not internalize HCV VLPs (data not shown). Thus, both DC-
SIGN and L-SIGN efficiently internalize HCV VLPs, but the
internalization pathway is dependent on the cell type, suggest-
ing that cellular origin is important. Therefore, we investigated
antigen uptake with DC-SIGN on primary cells.
DC-SIGN on DCs targets HCV to early endosomes. DCs
express high levels of various pathogen receptors such as DC-
SIGN (Fig. 4A) and the mannose receptor (12). We investi-
gated the interaction of immature DCs with the different HCV
envelope glycoproteins. The contribution of DC-SIGN on im-
mature DCs in the binding to HCV envelope glycoproteins was
investigated with specific blocking antibodies. Immature DCs
showed strong binding to HCV E1, E2, and E1/E2 VLPs. This
binding could be blocked by a specific anti-DC-SIGN antibody,
mannan, and EGTA, but not by an antibody against mannose
receptor (Fig. 4B), demonstrating that DC-SIGN is the major
receptor for HCV envelope glycoproteins on immature DCs.
Moreover, mature DCs also captured the different HCV
envelope glycoproteins, and this could be blocked by mannan,
EGTA, and an antibody against DC-SIGN but not by a man-
nose receptor-specific antibody (Fig. 4C). This indicates that
on mature DCs, DC-SIGN is also the major receptor for HCV
envelope glycoproteins. However, this binding was less strong
than the binding by immature DCs due to downregulation of
DC-SIGN expression (Fig. 4A).
Next, we investigated the effect of HCV on DC activation
and maturation. Activation was determined by measuring the
expression levels of the maturation markers CD83 and CD86.
Immature DCs were incubated with HCV VLPs for 48 h.
CD83 and CD86 expression did not change compared to that
in DCs incubated without HCV (Fig. 4D), demonstrating that
HCV VLPs do not induce maturation. We have demonstrated
that mycobacterial lipoarabinomannan binding to DC-SIGN
prevents DC activation (19). In contrast, HCV had no effect on
LPS-induced DC activation (Fig. 4D). This supports recent
data showing that DCs function normally in chronic HCV-
infected patients (30), suggesting that HCV evades DC immu-
nity in a different way. Therefore, the fate of HCV VLPs upon
binding by immature DCs was investigated.
Immature DCs were incubated with HCV VLPs for 4 h or
overnight, and colocalization with the lysosomal marker
LAMP-1 or early endosomal markers EEA-1 (35) and trans-
ferrin was analyzed. After 4 h, colocalization of the HCV VLPs
was observed with transferrin-positive but not with LAMP-1-
positive vesicles. Even after 24 h, HCV was still present pri-
marily in EEA-1-positive vesicles (Fig. 5A), as was observed
for THP-1 transfectants (Fig. 3D and E). HCV VLP internal-
ization was DC-SIGN dependent, since blocking of DC-SIGN
with a DC-SIGN antibody completely abolished internalization
of HCV VLPs (data not shown). Subsequently, DC-SIGN co-
localization with HCV VLPs after incubation was investigated.
After incubation at 4°C, both HCV VLPs and DC-SIGN were
localized at the surface of the DCs (Fig. 5B). When incubated
at 37°C for 4 h to allow internalization, internalized HCV
VLPs colocalized with DC-SIGN (Fig. 5B). Even after pro-
longed incubation (24 h), DC-SIGN colocalized with HCV
VLPs, suggesting that, besides a role in internalization, DC-
SIGN has a role in intracellular routing of HCV VLPs.
Strikingly, the internalization pathway of DC-SIGN on im-
mature DCs is dependent on the ligand, since the carbohydrate
blood group antigen Lewis X and mycobacterial ManLAM
were efficiently captured and internalized by immature DCs
through DC-SIGN and targeted to transferrin negative,
LAMP-1-positive lysosomes (Fig. 5C) (19) but not on the li-
gand-binding site, as ManLAM binds the same site as HCV E1
and E2 and HIV gp120. Together, these data suggest that
HCV targets DC-SIGN to enter DCs and escape degradation
by preventing targeting to the lysosomes.
HCV interact with LSECs in situ. In the liver, hepatocytes
are the main target of HCV, and although putative HCV
receptors have been identified, it is unclear how HCV infects
hepatocytes. We have shown that cell lines transfected with
L-SIGN can interact with HCV envelope glycoproteins (Fig.
2). L-SIGN is expressed on LSECs (5, 37), the liver sinusoidal
endothelial cells that are in close contact with the blood and
could capture HCV from the blood and transmit it to the
hepatocytes. However, these cells are difficult to isolate. There-
fore, we used an in situ binding assay to investigate the major
HCV binding cells in the liver.
L-SIGN was stained in liver tissue sections with an anti-L-
SIGN antibody and analyzed by immunofluorescence microscopy
(Fig. 6A). HCV envelope glycoprotein binding in situ was inves-
tigated by incubating the liver sections with HCV VLPs. VLPs
were detected with anti-HCV E1 antibody and fluorescently la-
beled secondary antibody (Fig. 6B). The staining pattern of HCV
TABLE 1. Identification of ligand binding site of DC-SIGN for
HCV and HIV-1 envelope glycoproteins
DC-SIGN expressed
by K562 transfectant
Fluorescent bead adhesion
gp120 E1 E2
Wild type 45 50 45
E347Q 4 3 7
N349D 0 5 9
N356D 0 5 9
D366A 3 4 5
D320A 7 4 6
E324A 0 4 7
N350A 1 4 8
D355A 2 4 8
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VLPs was similar to that of L-SIGN staining in the sections,
suggesting that the HCV binds to L-SIGN-expressing LSECs.
Moreover, HCV binding to LSEC was specifically inhibited by a
blocking antibody against L-SIGN (Fig. 6C), demonstrating that
this binding was mediated by the C-type lectin L-SIGN. Strikingly,
HCV VLPs interacted only with the LSECs and not with hepa-
tocytes that express the putative HCV receptor asialoglycoprotein
receptor and are the main target cells for HCV. These data
suggest that HCV is captured by L-SIGN that mediates internal-
ization of HCV, and thus LSECs act as an HCV reservoir and
may transmit the virus to hepatocytes.
DISCUSSION
Our results demonstrate that HCV is efficiently captured by
DCs through DC-SIGN and by LSECs through L-SIGN. The
FIG. 3. Internalization pathway of DC-SIGN and L-SIGN is dependent on cellular background. (A) DC-SIGN and L-SIGN expressed by K562
and THP-1 transfectants bind HCV VLPs similarly. Binding of HCV E1/E2 VLP to K562 and THP-1 transfectants with both DC-SIGN and
L-SIGN was measured. Interaction was blocked by the DC-SIGN- and L-SIGN-specific antibody AZN-D2 (50 g/ml). Standard deviations were
5%. (B to E) DC-SIGN- or L-SIGN-bound HCV is targeted to the early endosomes (transferrin positive) in THP-1 transfectants, in contrast to
the lysosomal (LAMP-1 positive) targeting in K562 transfectants. K562 (B and C) and THP-1 (D and E) cells expressing DC-SIGN or L-SIGN
were incubated overnight with HCV VLPs. HCV was detected with a human anti-HCV antibody and a FITC-labeled secondary antibody.
Intracellular targeting was determined by staining the endosomal compartments with a mouse antibody against the lysosomal and late endosomal
LAMP-1-specific and Alexa Fluor 594-labeled secondary antibody (B and D) or by coincubating the cells for 15 min with Alexa Fluor 594-labeled
transferrin, which is specifically transported to the early endosomes (C and E). Cells were analyzed by fluorescence microscopy.
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C-type lectins interacted with both envelope glycoproteins E1
and E2. Strikingly, internalized HCV VLPs were targeted by
DC-SIGN on immature DCs to early endosomal compart-
ments, where HCV is protected from degradation. Similarly,
HCV captured by L-SIGN expressed on THP-1 was targeted to
early endosomal compartments. In contrast, another ligand of
DC-SIGN, Lewis X blood group antigen, was targeted to the
lysosomes. Thus, HCV may target DC-SIGN and L-SIGN to
use DCs and LSECs, respectively, as reservoirs to facilitate
viral dissemination.
Because of the lack of a suitable cell culture system for in
vitro propagation of HCV and the unavailability of virions in
sufficient quantities, truncated and secreted versions of the
HCV envelope glycoproteins have been used as soluble surro-
gates for native virus particles. Here, we used VLPs of HCV
envelope glycoproteins E1 and E2. The envelope glycoproteins
E1 and E2 were produced in either the yeast H. polymorpha or
mammalian cells with a recombinant vaccinia virus and assem-
bled into a VLP of noncovalently linked E1 or E2 homomers
or E1/E2 heteromers. We used these purified HCV VLPs to
investigate their interaction with both DC-SIGN and L-SIGN.
Both cellular DC-SIGN and L-SIGN bound strongly to en-
velope glycoproteins E1 and E2 alone as well as to the E1/E2
heterodimer particles (Fig. 2). The interactions were specifi-
cally inhibited by blocking antibodies against DC-SIGN and
L-SIGN. Recently, it was shown that both DC-SIGN and L-
SIGN interact with HCV envelope glycoprotein E2 (14, 31, 38)
and envelope glycoprotein E1 (38). Here we demonstrate that
DC-SIGN bound more strongly to envelope glycoprotein E2
than to glycoprotein E1. Lozach et al. (31) demonstrated that
the interaction of DC-SIGN with glycoprotein E2 is dependent
on N-linked glycosylations. HCV envelope glycoprotein E2 has
11 potential N-linked glycosylation sites, whereas envelope gly-
coprotein E1 has only six sites (34), which can explain the
stronger binding of DC-SIGN to HCV envelope glycoprotein
E2. Furthermore, we demonstrate that the interactions of DC-
SIGN with HCV envelope glycoproteins E1 and E2 and with
HIV-1 envelope protein gp120 were equally dependent on
calcium (Fig. 1E), suggesting that these viral envelope glyco-
proteins interact at the same binding site in DC-SIGN.
Indeed, site-directed mutagenesis demonstrated that both
HCV glycoproteins E1 and E2 bound the primary ligand-bind-
ing site in DC-SIGN through coordination with the primary
Ca2 ion at site 2 (Table 1). Moreover, HCV envelope glyco-
proteins E1 and E2, like the pathogenic ligands HIV-1 gp120
and mycobacterial ManLAM, bound to the V351G DC-SIGN
mutant, whereas the cellular ligand ICAM-3 does not bind this
mutant (17, 19). These observations further suggest that DC-
SIGN may distinguish between different types of ligand and
ceptor antibody (clone 19) (50 g/ml). Standard deviations were5%.
(D) HCV VLPs do not affect DC activation or maturation. Immature
DCs were incubated with HCV (12.5 g/ml) alone, LPS (10 g/ml)
alone, or HCV and LPS together for 48 h, and activation was deter-
mined by measuring the expression of CD83 and CD86. Dotted lines,
isotype controls; solid histograms with thin lines, incubations without
HCV; open histograms with thick lines, incubations without or with
LPS in combination with HCV VLPs. Upper panel, incubations with-
out LPS; lower panel, incubations with LPS. One representative ex-
periment out of three is shown.
FIG. 4. DCs strongly bind to HCV glycoprotein E1 and E2 through
DC-SIGN. (A) Immature DCs express high levels of DC-SIGN. LPS-
matured DCs express lower levels of DC-SIGN. Monocyte-derived
DCs were isolated as described in Materials and Methods. Expression
of DC-SIGN was measured by fluorescence-activated cell sorting stain-
ing with the DC-SIGN-specific antibody AZN-D2. Open histograms,
isotype control; solid histograms, AZN-D2 staining. (B and C) Imma-
ture DCs and mature DCs bind strongly to HCV envelope glycopro-
teins E1 and E2 and mixed HCV E1/E2 VLPs via DC-SIGN. Imma-
ture (B) and LPS-matured (C) DC binding to HCV envelope
glycoproteins was determined by a fluorescent bead adhesion assay.
Specificity was determined by anti-DC-SIGN antibody AZN-D2 (50
g/ml), mannan (100 g/ml), EGTA (10 M), and anti-mannose re-
8328 LUDWIG ET AL. J. VIROL.
may tailor its responses specifically to the ligand that it recog-
nizes.
DC-SIGN functions as a more universal pathogen receptor
(46), and the pathogens HIV-1 and M. tuberculosis target DC-
SIGN to escape immune surveillance (15, 19, 27). The inter-
action of HCV envelope glycoproteins E1 and E2 with both
DC-SIGN and L-SIGN suggests that DC-SIGN and L-SIGN
may be involved in the pathogenesis of HCV. Little is known
about the dissemination of HCV, and the role of the immune
system in the pathogenesis of HCV is complex and largely
unknown. It has been shown that HCV may affect DCs; during
chronic HCV infection, DCs are impaired in their immune
function (3, 4). In contrast, a recent study demonstrated that
monocyte-derived DCs from patients suffering from chronic
HCV infection are functionally normal (30). Here we demon-
strate that immature DCs bind strongly to HCV envelope
glycoprotein E1, E2, and E1/E2 VLPs through DC-SIGN,
since the interactions were completely blocked by antibodies
against DC-SIGN (Fig. 4B). Mature DCs also captured HCV
E1, E2, and E1/E2 VLPs through DC-SIGN, although less
efficiently than immature DCs (Fig. 4C). This may be due to
the lower expression of DC-SIGN on mature DCs than on
immature DCs (Fig. 4A) (38). The complete inhibition of the
interaction of both immature and mature DCs with HCV par-
ticles by antibodies against DC-SIGN demonstrates that DC-
SIGN is the primary receptor for HCV on both immature and
mature DCs, not the HCV E2 receptor CD81, which is also
expressed by DCs (38).
HCV VLPs were rapidly internalized upon capture by both
DC-SIGN and L-SIGN (Fig. 3). Depending on the cell type,
the captured HCV VLPs were targeted differently to intracel-
lular compartments by these C-type lectins. In the cell line
THP-1, captured HCV VLPs were targeted to transferrin-
positive nonlysosomal compartments, whereas VLPs captured
by the erythroleukemic cell line K562, expressing either DC-
SIGN or L-SIGN, were targeted to LAMP-1-positive lysoso-
mal compartments (Fig. 3). These results demonstrate that
there is a difference in internalization pathway between these
cell lines. HCV VLPs captured by primary immature DCs
through DC-SIGN were targeted to early endosomal vesicles,
where they resided for over 24 h, similar to the THP-1 trans-
fectants. This indicates that the internalization pathway ob-
served in THP-1 transfectants may represent a more native
situation, as found in DCs. In addition, it was recently dem-
onstrated that transmission of HIV-1 is also cell type depen-
dent (45). DC-SIGN does not facilitate HIV-1 infection of
DCs but protects the virus from degradation by internalizing
the virus in nonlysosomal compartments (15, 27). The DC-
SIGN-bound HIV-1 is efficiently transmitted to recipient
secondary antibody. Cells were analyzed on a 3i Marianas digital im-
aging microscopy workstation with SlideBook software. (C) DC-SIGN
on immature DCs targets its ligand Lewis X antigen to late endosomes
and lysosomes. Immature DCs were incubated with Lewis X (10 g/
ml) for 4 h. Intracellular targeting was determined by staining the
endosomal compartments with a mouse antibody against the lysosome-
and late endosome-specific marker LAMP-1 or by coincubating the
cells for 15 min with Alexa Fluor 594-labeled transferrin, which is
specifically transported to early endosomes. Cells were analyzed by
fluorescence microscopy.
FIG. 5. DC-SIGN on immature DCs targets HCV VLPs to early
endosomes but Lewis X antigen to lysosomes. (A) Immature DCs were
incubated with HCV VLPs (30 g/ml) for 4 h or overnight. HCV was
detected with a human anti-HCV antibody and a FITC-labeled sec-
ondary antibody. Intracellular targeting was determined by staining the
endosomal compartments with a mouse antibody against the lysosome-
and late endosome-specific marker LAMP-1 or the early endosome-
specific marker EEA-1 and an Alexa Fluor 594-labeled secondary
antibody or by coincubating the cells for 15 min with Alexa Fluor
594-labeled transferrin, which is specifically transported to early endo-
somes. (B) Immature DCs were incubated with HCV VLPs (30 g/ml)
for 4 h or overnight at 37 or 4°C. HCV was detected as described for
panel A. Localization of DC-SIGN was determined with the DC-
SIGN-specific antibody AZN-D2 and an Alexa Fluor 594-labeled sec-
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CD4 T cells upon coculture of DCs with CD4 T cells, which
results in a productive infection of T cells (15).
Like DCs, THP-1 cells expressing DC-SIGN continue to
infect T cells with HIV-1 for several days, whereas DC-SIGN-
expressing 293 cells are infective only for a short period. How-
ever, HIV-1 is not retained in early endosomal compartments
like HCV or in lysosomes but in other, undefined vesicles (27,
45), which may explain why transmission in these cells is pos-
sible over a prolonged period. The internalization pathway of
DC-SIGN-bound ligands is dependent not only on the cell type
but also on the ligand, as another carbohydrate-containing
ligand of DC-SIGN, Lewis X antigen, was rapidly internalized
and targeted to the lysosomal compartment in both immature
DCs and THP-1 transfectants (Fig. 5C and data not shown).
Altogether, these results support a role for DC-SIGN in the
capture of HCV virions by immature DCs, similar to HIV-1,
and show that THP-1 transfectants are a suitable model for
pathogen internalization. A recent study suggests that the
THP-1 cells used to study DC-SIGN and L-SIGN function
have B-cell-like characteristics (48). Indeed, the THP-1 cells
used in this study express CD19 (data not shown) and there-
fore may be of B-cell origin. Interestingly, B cells have an
antigen-processing and -presenting machinery similar to that
of DCs, and our results demonstrate that DC-SIGN expressed
by these THP-1 cells behaves as it does on immature DCs.
Therefore, THP-1 cells are a suitable model for studying
pathogen internalization.
Hepatocytes are productively infected by HCV, and the hep-
atocyte-specific asialoglycoprotein receptor has been proposed
as an HCV receptor (41). However, we demonstrate here that
not hepatocytes but LSECs bind HCV VLPs in primary liver
tissue (Fig. 6), suggesting that LSECs capture HCV from the
blood and transfer HCV to hepatocytes. Moreover, L-SIGN,
like DC-SIGN, has been shown to function in HIV-1 transmis-
sion (5), and L-SIGN expressed by LSECs, could capture HCV
from the blood and transfer it to hepatocytes. A similar mech-
anism was demonstrated for another hepatic virus, hepatitis B
virus (6). This virus enters LSECs, and Breiner et al. (6) pro-
posed that the virus travels via endosomal compartments to the
hepatocytes that are subsequently infected. Our data further
indicate that both LSECs and DCs may efficiently capture and
protect the virus and function as HCV reservoirs.
Our recent results suggest that mycobacteria target DC-
SIGN by secreting ManLAM to downregulate DC-mediated
immune responses and thus promote pathogen survival (19). It
is not clear whether viruses are able to suppress DC functions
by binding DC-SIGN through a similar mechanism. The im-
munosuppressive setting that characterizes infections with cy-
tomegalovirus and HIV-1, two viruses that interact with DC-
SIGN, implies that such a mechanism of immunomodulation
may exist (reviewed in reference 46). It was suggested that DCs
isolated from patients suffering from chronic HCV infections
have an impaired maturation and immune-stimulatory func-
tion (3, 4). However, our data indicate that immature DCs are
not affected by HCV VLPs, and furthermore, Longman et al.
recently showed that DCs from chronically infected patients
are not impaired in their immune function (30). This suggests
that HCV may target DC-SIGN to escape lysosomal degrada-
tion in DCs and thereby evade immunity. Although further
investigations into the function of DC-SIGN and L-SIGN will
FIG. 6. HCV interacts with L-SIGN-expressing LSECs in situ.
(A) L-SIGN is expressed by human LSECs, as was determined by
staining of liver tissue with an L-SIGN-specific antibody. (B) Binding
of HCV VLPs by liver tissue was determined by incubating liver sec-
tions with HCV VLPs (10 g/ml) for 2 h at 37°C. HCV binding was
detected with a human anti-HCV antibody and FITC-labeled second-
ary antibody. (C) HCV VLP binding to LSECs is specifically blocked
by the L-SIGN-specific antibody AZN-D2. Sections were incubated
with AZN-D2 (50 g/ml) for 30 min at room temperature before HCV
VLPs were added as described for panel A. Sections were analyzed by
fluorescence microscopy with a 20 objective. Bars, 50 m.
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be necessary to determine their importance in HCV infections,
our results suggest that both DC-SIGN and L-SIGN may be
potential targets for designing strategies to combat HCV in-
fections.
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